Adam’s Journal Here’s a question from an Oklahoma Medical Research Foundation coworker: I’ve seen articles claiming semaglutides like Ozempic and Wegovy can reduce the risk for a rash of conditions, including dementia and alcohol use disorder. Is it the medicine having this impact, or is it the resulting weight loss? Dr. Scofield Prescribes The class […]
Zepbound
Bodywork: The latest news about weight-loss drugs
Each week, OMRF Chief Medical Officer Dr. Judith James opens “Adam’s Journal” to answer a medical question from Adam Cohen, OMRF’s senior vice president & general counsel. Adam’s Journal I’ve seen a lot of headlines recently about the new generation of weight-loss drugs. Now that their use is becoming more widespread, what are we learning […]
Bodywork: Getting the skinny on weight-loss drugs
A new weight-loss drug was recently approved. How is it different from the options on the market?
